-

Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, today announced that it will report third quarter 2026 financial results after the market closes on Monday, November 9, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.

The conference call can be accessed by dialing (833) 461-5787 for U.S. participants and (585) 542-9983 for international participants, referencing meeting ID 461 746 058. A live audio webcast will be available at https://investors.hims.com and will be archived for one year.

About Hims & Hers Health, Inc.

Hims & Hers is the leading global health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit https://investors.hims.com/.

Contacts

Investor Relations
Bill Newby
Investors@forhims.com

Media Relations
Abby Reisinger-Moley
Press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Investor Relations
Bill Newby
Investors@forhims.com

Media Relations
Abby Reisinger-Moley
Press@forhims.com

More News From Hims & Hers

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

INDIANAPOLIS--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform. The agreement brings together Lilly’s obesity med...

Hims & Hers Benefits Adds Grüns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced four new partners joining Hims & Hers Benefits: Grüns®, Medjet®, Tonal™, and Viome™. The program launched in March with two partners and has grown to include 14, with benefits designed to support subscribers’ whole-body health, including through a GLP-1 weight loss journey. "Building health is an everyday activity. It starts with understanding your body and co...

Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men’s Health Launch to Date

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the launch of new injectable and oral testosterone replacement therapies (TRT) for eligible men. It’s the largest expansion of the company’s men’s health program since first introducing the category last September, giving eligible men more options to treat low testosterone in partnership with licensed providers through Hims. An estimated 20 million men1,2 i...
Back to Newsroom